Cell Lysis and Disruption Market

Market Overview

The global cell lysis and disruption market size was valued at USD 4,854.4 million in 2022. It is estimated to reach USD 10,456.6 million by 2031, growing at a CAGR of 8.9% during the forecast period (2023–2031). The projected increase in research endeavors pertaining to cell line creation and mammalian research is expected to have a favorable influence on market expansion over the forecast period. The creation of new lysis reagents and techniques, along with ongoing innovation in the sector, can boost the market's potential for expansion. The field of stem cell research is growing, and as isolating and analyzing stem cells calls for effective cell lysis techniques, there is a market niche for cell lysis technology.

The process of rupturing or dismantling cell membranes and structures to liberate cellular components is referred to as cell lysis and disruption. Numerous uses for this procedure exist, such as protein separation, further processing, cell organelle separation, and nucleic acid extraction. Mechanical, chemical, enzymatic, and other techniques can all be used to lyse and disturb cells. Mechanical procedures utilize high-pressure homogenization, sonication, bead milling, or grinding to disrupt the cells. While enzymatic methods use enzymes to break down cell components and release the target chemicals, chemical approaches lyze the cells using detergents or organic solvents.

Market Dynamics

Cell Lysis and Disruption Market Drivers

Rising Government Funding for Research

The rise in investments by several government and non-government organizations toward R&D related to biotechnological processes and academics is expected to drive the market significantly. For instance, the German government has emphasized higher education and research through several strategies and initiatives nationwide. These include the Internationalization Strategy, the new High-Tech Strategy, the Excellence Strategy, and the Excellence Initiative (2005–2017).

Moreover, federal and state governments in Germany offer nearly 30% of spending on R&D in the country and have collaborated to fund important national projects. Similarly, the federal government of Canada supports innovation and economic development of the country’s life sciences industry. The market is expected to be favorably affected by the increase in research efforts related to cell line development and mammalian research over the forecast period.

Application of Cell Lysis and Disruption Methods in Novel Gene Expression Protocols

Increased interest in single-cell analysis has successfully implemented gene-expression profiling in preimplantation genetic diagnosis (PGD) and other diagnostic applications. Owing to technological advancements, the gene expression profiles of patients can be measured with higher accuracy and precision. This is anticipated to create novel opportunities in the area of molecular medicine. In addition, reverse transcription-quantitative real-time PCR is a commonly used single-cell gene expression profiling method. As cell lysis is part of the process workflow, a rise in the adoption of gene expression protocols is expected to provide growth opportunities in the market.

Cell Lysis and Disruption Market Restraint

High Cost Associated with Instrument Set-Up

The high cost of cell-based research and therapies, especially stem cell-based therapy, is a major restraint for market growth. The cost of stem cell therapy varies considerably depending on the region, specific treatment, and doctor/hospital. Most of the clinics in the U.S. charge anywhere between USD 7,000 and USD 10,000 per treatment. Similarly, according to CBC Canada, stem cell therapy ranges from USD 5,000 to USD 8,000 per stem cell treatment. However, in clinics outside the U.S., treatment costs range from USD 20,000 to USD 100,000. This is a major restraint for the market as insurance providers do not cover these therapies, increasing out-of-pocket expenditure.

Cell Lysis and Disruption Market Opportunities

Advancements in Homogenizers, Instruments, and Chemical Lysis Methods

Advancements in cell lysis and disruption instruments are anticipated to drive revenue generation in the market. Several advanced iterations of homogenizers have been recently introduced to the market. Ultrasonic homogenizers offer a versatile means of selectively lysing specific samples. This decreases the overall time of sample preparation and increases the reaction yield. These homogenizers also exhibit higher efficiency when compared to gap/rotor/stator homogenizers, planetary ball mills, and other mechanical processing devices. These features have increased the applications of ultrasonic homogenizers in various fields of medicine and biochemistry.

Furthermore, the advent of instruments based on the hub-and-spoke principle is anticipated to increase the adoption rate of cell lysis and disruption instruments. These systems are more efficient than traditional shaking systems, facilitate the use of small motors, generate less heat, and are efficient in homogenizing roots, carcinoma, and muscle. Moreover, these systems are cost-effective, which further enhances the utility rate in the cell lysis process.

Regional Analysis

North America Dominates the Global Market

Based on region, the global cell lysis and disruption market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America is the most significant global cell lysis and disruption market shareholder and is estimated to exhibit a CAGR of 8.11% over the forecast period. The presence of innovators and key players has increased the market penetration of products in the region. North America leads the cell lysis and disruption market and other emerging markets that require strong biotechnology and R&D presence, such as genomics, proteomics, oncology, diagnostic screening, and drug discovery. In addition, universities in the U.S. and Canada conduct highly-ranked genetic research programs. These have driven North America's demand for cell lysis and disruption methods.

Moreover, the rising prevalence of chronic disorders and the adoption of personalized medicine approaches in treating life-threatening disorders would drive market growth. A strong regulatory framework for drug approval is one of the major drivers accelerating the demand for efficient cell lysis methods in this region.

Europe is expected to exhibit a CAGR of 9.1% over the forecast period. This is primarily due to support received from government and non-government organizations for R&D and commercial production of biotherapeutics. Major European countries considered within the market space include the UK and Germany. However, European countries with a strong regional position include France, Sweden, Switzerland, Norway, Denmark, Italy, Austria, and the Netherlands. Denmark and Norway have increased the uptake of infliximab biosimilars because of a tender system to pay for the medicines in the country.

Furthermore, the presence of national and international organizations, such as the European Union (EU) and the European Bioinformatics Institute (EBI), further accelerates the region's progress. These organizations also fund numerous genomic projects conducted by researchers across European countries. Cell disruption techniques play a vital role in metagenomics studies; therefore, developments in the metagenomics field will propel the growth of the European cell lysis and disruption market.

Asia-Pacific is the fastest-growing global cell lysis and disruption market region. Japan and China are the most attractive markets in the region, with high investments in precision medicine and omics technologies. Other Asian countries are also making moves to compete in the market. Key players in Singapore are making efforts to make the country a hub for healthcare innovation in Asia, with a significant interest in biotechnology. In addition, continuous reforms in the healthcare and biotechnology sectors in the region would further boost market growth. The large population and untapped potential in the region have led to a shift in the businesses of the global firms in this region. Moreover, research, manufacturing, and operation unit costs are lower than in other regions.

Segmental Analysis

The global cell lysis and disruption market is bifurcated into technique, product, cell type, application, and end-user.

Based on technique, the global cell lysis and disruption market is bifurcated into reagent-based, physical disruption, and pressure.

The reagent-based segment dominates the global market and is projected to exhibit a CAGR of 8.9% over the forecast period. Detergent-based cell disruption and lysis methods have gained popularity over physical disruption methods. This is because these methods do not destroy the biological activity of the final products, are mild, and are ideally suited for laboratory samples. With the help of empirical testing methods, several detergent-based solutions consisting of concentrations and particular types of reducing agents, salts, buffers, and detergents have been manufactured to provide the best possible results for specific cell types and species.

Reagent-based methods are sometimes combined with mechanical disruption methods such as sonication. These methods include using enzymes and detergents and are generally available as kits. However, these methods are sometimes unpredictable, as the duration and disruption conditions of different samples vary significantly. Moreover, kits prove to be a recurring expense for users.

Based on product, the global cell lysis and disruption market is bifurcated into instruments, reagents, and consumables.

The reagents and consumables segment owns the highest market share and is predicted to exhibit a CAGR of 8.9% over the forecast period. Reagents and consumables are the most widely used products for cells. Ease of use and specificity toward various biological materials can be attributed to segment growth. A relatively high rate characterizes the adoption of reagents due to their non-detrimental impact on the cultured cells. Moreover, using reagents eliminates all the limitations incurred during instrument use. For instance, reagents do not utilize any mechanical energy and do not produce any heat during operation. However, reagents and instruments are sometimes used to enhance cell lysis efficiency. Moreover, the adoption of detergents and enzymes is higher in laboratories as they can be customized to work for specific cell types.

Based on cell type, the global cell lysis and disruption market is segmented into mammalian cells, bacterial cells, yeast/algae/fungi, and plant cells.

The mammalian cells segment dominates the global market and is predicted to exhibit a CAGR of 8.2% during the forecast period. Mammalian cell cultures are lysed with the help of osmotic lysis, freeze-thaw lysis, detergent and enzymatic lysis, sonication, French press, and glass-bead homogenization methods. Sigma-Aldrich provides CelLytic products, a range of reagents for protein extraction. These reagents are specifically curated to extract and lyse cellular proteins based on different expression systems. These reagents work with various chaotropic, chelating agents, and protease inhibitors.

Moreover, these can be conveniently scaled up as required. These are also used for the lysis of mammalian cells. Similarly, Merck Millipore provides a range of mammalian cell lysis reagents to prepare mammalian phosphorylated, cytosolic, and nuclear proteins. Some of the common mammalian cell lysis products offered by the company include CytoBuster protein extraction reagent, NucBuster protein extraction kit, PhosphoSafe extraction reagent, and ProteoExtract kits.

Based on application, the global cell lysis and disruption market is divided into protein isolation, downstream processing, cell organelle isolation, and nucleic acid isolation.

The protein isolation segment is the most significant contributor to the market and is expected to exhibit a CAGR of 8.71% over the forecast period. Protein isolation is one of the most important applications of cell lysis and disruption techniques. The major areas of focus include proteomics, western blotting, and immunoprecipitation. The demand for cell lysis and disruption techniques has increased in the field of proteomics owing to developments in proteogenomics, drug discovery, and the role of proteomics in treating and diagnosing life-threatening disorders such as cancer, cardiac disorders, and neurodegenerative diseases. Cell disruption techniques used during protein isolation include grinding the sample in liquid nitrogen, sonication, bead beating, and disruption through reagents.

Based on end-users, the global cell lysis and disruption market is divided into academic and research institutes, hospitals and diagnostic labs, cell banks, and pharmaceutical and biotechnology companies.

The academic and research institutes segment is the major contributor to the market and is estimated to exhibit a CAGR of 9.9% over the forecast period. Academic and research institutes include universities, laboratories, and research institutions that carry out molecular biology experiments. These institutes carry out cell lysis, disruption, and fractionation in their labs for training, education, and research purposes. In addition, the growth of the biotechnology sector and a rise in the number of researchers in the field are expected to drive the market. This is due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries. Moreover, gene therapy and genetic engineering developments would further propel market growth as recombinant products are in higher demand.

Recent Developments

• July 2023: Merck Millipore introduced MilliporeSigma Cell Culture Media, a new mammalian cell culture product. MilliporeSigma Cell Culture Media is intended to suit the demands of researchers and manufacturers seeking high-quality, dependable media.
• February 2023: STEMCELL Technologies, a prominent manufacturer of cell culture medium and reagents, was acquired by Thermo Fisher Scientific. The purchase will likely improve Thermo Fisher's position in the mammalian cell market.